$AXIM
AXIM BIOTECHNOLOGIES, INC.

2014 Q1 Form 10-K Financial Statement

#000151495514000003 Filed on March 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013
Revenue $0.00 $21.67K
YoY Change -100.0% -50.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.00K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $10.00K $110.9K
YoY Change 90.4%
Operating Profit
YoY Change
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $778.00
YoY Change -83.52%
Pretax Income -$10.00K -$60.00K
YoY Change 500.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.00K -$89.22K
YoY Change 71.91% 498.62%
Net Earnings / Revenue -411.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$303.00 -$2.727K
COMMON SHARES
Basic Shares Outstanding 33.00M shares 33.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change -100.0%
Cash & Equivalents $127.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $0.00 $3.127K $0.00
YoY Change -100.0% -92.01% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $50.00K $53.70K $60.00K
YoY Change -45.17% -42.69% -33.33%
TOTAL ASSETS
Total Short-Term Assets $0.00 $3.127K $0.00
Total Long-Term Assets $50.00K $53.70K $60.00K
Total Assets $50.00K $56.82K $60.00K
YoY Change -60.2% -57.22% -53.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $50.00K
YoY Change 66.67%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $50.00K $50.00K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.00K $150.7K $150.0K
YoY Change -55.93% 9.61% 7.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $60.00K $150.7K $150.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $60.00K $150.0K
YoY Change 7.14%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $3.300K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.00K -$93.92K -$90.00K
YoY Change
Total Liabilities & Shareholders Equity $50.00K $56.82K $60.00K
YoY Change -60.2% -57.22% -53.85%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$10.00K -$89.22K
YoY Change 71.91% 498.62%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities $0.00 -$30.00K
YoY Change -100.0% -242.15%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 10.00K
YoY Change -86.65%
NET CHANGE
Cash From Operating Activities 0.000 -30.00K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 10.00K
Net Change In Cash 0.000 -20.00K
YoY Change -100.0% 398.75%
FREE CASH FLOW
Cash From Operating Activities $0.00 -$30.00K
Capital Expenditures $0.00
Free Cash Flow $0.00
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013 axim Acquisition Extension Expense
AcquisitionExtensionExpense
10000 USD
CY2012 axim Acquisition Extension Expense
AcquisitionExtensionExpense
USD
CY2013 axim Monthly Professional Fees
MonthlyProfessionalFees
3000 USD
CY2013Q4 axim Portion Of Joint Purchase Attributed To Company
PortionOfJointPurchaseAttributedToCompany
260000 USD
CY2013Q4 axim Working Capital Needed To Fund Purchase Of Technology
WorkingCapitalNeededToFundPurchaseOfTechnology
20000 USD
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001514946
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33000000 shares
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 dei Entity Public Float
EntityPublicFloat
0 USD
CY2013 dei Entity Registrant Name
EntityRegistrantName
AXIM INTERNATIONAL INC.
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
52988 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
32570 USD
CY2013Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
11000 USD
CY2012Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
20000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11700 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11700 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8000 USD
CY2012Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
30985 USD
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
USD
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5472 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16304 USD
CY2013Q4 us-gaap Assets
Assets
56823 USD
CY2012Q4 us-gaap Assets
Assets
132824 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
3127 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
39128 USD
CY2013Q4 us-gaap Cash
Cash
127 USD
CY2012Q4 us-gaap Cash
Cash
19128 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19128 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23138 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2013 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-19001 USD
CY2012 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4010 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
127 USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33000000 shares
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
3300 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3300 USD
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 100%; PADDING-LEFT: 0%; PADDING-RIGHT: 0%"> <!--StartFragment--> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> Concentrations</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> The Company has an exclusive marketing arrangement to license and operate a waste disposal system in the sales territory of East Jamaica W.I.&nbsp; It is committed under that license agreement to purchase and install one of these systems by December 31, 2014.&nbsp; The Company has entered into a joint venture agreement with a third party to develop and operate the system.</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> As described in Note 1 the Company has entered into a similar exclusive marketing arrangement for a second territory.&nbsp; Under this arrangement the Company is committed to purchase and install a second system before December 31, 2014.&nbsp; The territory consists of West Jamaica and various Caribbean countries as listed in Note 1.&nbsp; Based on these facts the Company has concentrations in product and geographic area.</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 8pt; MARGIN: 0cm 0cm 0pt"> &nbsp;</p> <!--EndFragment--></div> </div>
CY2013Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
50000 USD
CY2012Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
50000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21667 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16353 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2970 USD
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16353 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2970 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
109017 USD
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
19798 USD
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
45002 USD
CY2011Q3 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.001
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16304 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
53696 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93696 USD
CY2013 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
30000 USD
CY2012 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
30000 USD
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
USD
CY2012 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
1800 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20418 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
27070 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
52988 USD
CY2013 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
13383 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21667 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-43333 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
USD
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-9000 USD
CY2012 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-45000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
11000 USD
CY2013 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
450 USD
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
2750 USD
CY2013 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
8746 USD
CY2012 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
10008 USD
CY2013 us-gaap Interest Paid
InterestPaid
0 USD
CY2012 us-gaap Interest Paid
InterestPaid
USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56823 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132824 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150740 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
137522 USD
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 USD
CY2013 us-gaap Liquidity Disclosure Going Concern Note
LiquidityDisclosureGoingConcernNote
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 100%; PADDING-LEFT: 0%; PADDING-RIGHT: 0%"> <!--StartFragment--> <p style="MARGIN: 0cm 0cm 0pt"><strong style="font-family: Times New Roman; FONT-SIZE: 10pt">Note 9 - Going Concern</strong></p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> As noted, the Company has concentrations in Geographic area and product currently available.&nbsp; Additionally the Company has no projected future license fees and is committed to purchase and install an APS200 system before December 31, 2014.&nbsp; The culmination of that effort is dependent on the Company&#39;s ability to raise capital either by borrowing under convertible notes (Note 4) or by a combination of borrowing and the acquisition of funds by its joint venture partner and licensee.&nbsp; Any failure of these conditions could cause the Company to cease operations during the next year.</p> <!--EndFragment--></div> </div>
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 100%; PADDING-LEFT: 0%; PADDING-RIGHT: 0%"> <!--StartFragment--> <p style="MARGIN: 0cm 0cm 0pt"><strong style="font-family: Times New Roman; FONT-SIZE: 10pt">Note 1 - Nature of Operations</strong></p> <p style="MARGIN: 0cm 0cm 0pt"><strong style="font-family: Times New Roman; FONT-SIZE: 10pt">&nbsp;</strong></p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> Axim International Inc. (a development stage company) was incorporated in Nevada on November 18, 2010, with an objective to acquire, or merge with, an operating business.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> On October 2, 2011, the Company acquired exclusive marketing rights in the territory of East Jamaica to technology for converting organic waste to marketable by-products.&nbsp; The technology is named Advance Pyrolysis System 200 ("APS200").&nbsp; The cost of this technology grant is $50,000 which was paid in cash in April 2012, and royalty fees of 3% of any revenue generated from the technology.&nbsp; This technology grant is for a period of twenty years but could be terminated prematurely by the licensor if conditions specified in the agreement are violated.&nbsp; One of those conditions was that the Company purchase an APS200 system before June 30, 2013.&nbsp; Cost of that acquisition was to be $500,000.&nbsp; The Company extended the June 30 deadline until December 31, 2013 for a cash payment of $ 10,000. &nbsp;On December 29, 2013, the Company executed a further extension of the December 31, 2013 deadline until December 31, 2014 in consideration for an increase in the acquisition cost of the APS200 price of $ 20,000.&nbsp; &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> Simultaneous with the acquisition of the technology rights, the Company entered into a joint venture agreement (JVA) with Alpha International Marketing Corp (Alpha) for the purpose of establishing and operating the APS200 System.&nbsp; Under the terms of the JVA, each party was to contribute $250,000 toward the cost of the acquisition of the APS200 system by June 30, 2013.&nbsp; An initial licensing fee of $75,000 was paid to the Company by Alpha; the fee was paid in 15 monthly installments of $5,000 between November 2011 and January 1, 2013.&nbsp; In addition, Alpha is obligated to pay the Company a royalty of 5% of any gross income earned from the APS200 System of which 2% will be retained by the Company and 3% shall be remitted to Omega.&nbsp; Profits from the joint venture are to be divided equally between the parties.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="color: black; font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> On March 25, 2013, the Company entered into an addendum to its joint venture agreement with Alpha.&nbsp; &nbsp;Alpha had defaulted on their license fee payments and the Company granted Alpha until June 30, 2013 to settle all amounts owed pursuant to the joint venture agreement.&nbsp; The joint venture agreement previously specified that in the event that the Company does not raise the $250,000 for the purchase of the APS200 by June 30, 2013, the Company would be liable to return license fees received from Alpha.&nbsp; Alpha has waived the Company&#39;s potential liability to return any license fees.&nbsp; This extension was further extended without contract to December 31, 2013.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> On December 30, 2013, the Company executed an agreement extending the acquisition of the APS200 system from January 1, 2014 until December 31, 2014 for consideration of $ 10,000 payable in installments commencing in 2014, in addition, the agreement requires an increase in the acquisition price to $ 520,000 whereby Alpha&#39;s portion of the purchase price would be $ 260,000.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> On November 26, 2012, the Company entered into a second licensing agreement with Omega Research Corporation ("Omega") for exclusive licensing rights for technology relating to the processing of organic waste to marketable byproducts via the Advanced Pyrolysis System 200 ("APS200"). The Company will have exclusive rights to sub-license, establish joint ventures to commercialize, use and process organic waste, and sell related byproducts in the territory of the Bahamas, Dominican Republic, St., Thomas, St. Maarten, and Grenada for 20 years.&nbsp; The Company acquired the licensing rights for $ 50,000.&nbsp; The Company has the obligation to purchase from Omega, the APS200 system at a fixed price of $ 500,000 by December 31, 2014.&nbsp; Subsequent to December 31, 2014, Omega may increase the purchase price at its sole discretion to reflect raising costs of raw materials and labor.&nbsp; The Company is subject to a royalty of 3% on any sub-licensee fees received as well as on gross sales from byproduct generated from the APS200 system.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> Effective July 20, 2012, the Company entered into a Convertible Loan Agreement with 4 lenders.&nbsp; The Agreement provides for a principle sum of $ 280,000 with interest of 10% per annum and is due 36 months after the dates of issuance.&nbsp; As of December 31, 2013, the Company had not received any of these funds and the lenders are under no obligation to lend the money.&nbsp; The Company intends to borrow the money as needed to fund the acquisition of the APS200 system.&nbsp; When and if issued, the principal sums of these loans will be convertible into common stock at the options of the lenders within 24 months of issuance dates.&nbsp; The loans will be convertible at $0.05 per share.&nbsp; The Agreement was entered into with non-U.S. persons.</p> <!--EndFragment--></div> </div>
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14017 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
74885 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
108002 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33018 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
21105 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7875 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-89219 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-14904 USD
us-gaap Net Income Loss
NetIncomeLoss
-109017 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
110886 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
58237 USD
us-gaap Operating Expenses
OperatingExpenses
184017 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2400 USD
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
109017 USD
CY2013 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
15000 USD
CY2012 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
USD
CY2013 us-gaap Other Expenses
OtherExpenses
778 USD
CY2012 us-gaap Other Expenses
OtherExpenses
4720 USD
CY2013 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
3636 USD
CY2012 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
9696 USD
CY2013 us-gaap Other General Expense
OtherGeneralExpense
USD
CY2012 us-gaap Other General Expense
OtherGeneralExpense
1970 USD
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
USD
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 USD
CY2011Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50000 USD
CY2012Q4 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000000 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
100 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
100 USD
CY2011Q3 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
Each preferred share has 100-1 votes.
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
USD
CY2012 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
50000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
50000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000 USD
CY2011Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000 USD
CY2013 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
14017 USD
CY2012 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
24885 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
45002 USD
CY2013 us-gaap Professional Fees
ProfessionalFees
23826 USD
CY2012 us-gaap Professional Fees
ProfessionalFees
23971 USD
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000 USD
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000 USD
CY2013 us-gaap Revenues
Revenues
21667 USD
CY2012 us-gaap Revenues
Revenues
43333 USD
us-gaap Revenues
Revenues
75000 USD
CY2013Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
2750 USD
CY2012Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
2300 USD
CY2013 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
USD
CY2012 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
USD
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-2100 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-93917 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-4698 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
10206 USD
CY2011Q3 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
13000000 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 100%; PADDING-LEFT: 0%; PADDING-RIGHT: 0%"> <!--StartFragment--> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> Use of estimates</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods.&nbsp; Actual results could differ from these estimates.</p> <p style="font-family: Times New Roman; FONT-SIZE: 10pt; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"> &nbsp;</p> <!--EndFragment--></div> </div>
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33000000 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33000000 shares

Files In Submission

Name View Source Status
0001514955-14-000003-index-headers.html Edgar Link pending
0001514955-14-000003-index.html Edgar Link pending
0001514955-14-000003.txt Edgar Link pending
0001514955-14-000003-xbrl.zip Edgar Link pending
axim-20131231.xml Edgar Link completed
axim-20131231.xsd Edgar Link pending
axim-20131231_cal.xml Edgar Link unprocessable
axim-20131231_def.xml Edgar Link unprocessable
axim-20131231_lab.xml Edgar Link unprocessable
axim-20131231_pre.xml Edgar Link unprocessable
axim10k2013final.htm Edgar Link pending
axim2013exhibit311.htm Edgar Link pending
axim2013exhibit321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending